Cargando…
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
Antibody responses that correlated with reduced risk of HIV acquisition in the RV144 efficacy trial were assessed in healthy African volunteers who had been primed three times with HIV-DNA (subtype A, B, C) and then randomized into two groups; group 1 was boosted twice with HIV-MVA (CRF01_AE) and gr...
Autores principales: | Msafiri, Frank, Joachim, Agricola, Held, Kathrin, Nadai, Yuka, Chissumba, Raquel Matavele, Geldmacher, Christof, Aboud, Said, Stöhr, Wolfgang, Viegas, Edna, Kroidl, Arne, Bakari, Muhammad, Munseri, Patricia J., Wahren, Britta, Sandström, Eric, Robb, Merlin L., McCormack, Sheena, Joseph, Sarah, Jani, Ilesh, Ferrari, Guido, Rao, Mangala, Biberfeld, Gunnel, Lyamuya, Eligius, Nilsson, Charlotta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693996/ https://www.ncbi.nlm.nih.gov/pubmed/33158007 http://dx.doi.org/10.3390/microorganisms8111722 |
Ejemplares similares
-
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018) -
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
por: Joachim, Agricola, et al.
Publicado: (2016) -
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
por: Joachim, Agricola, et al.
Publicado: (2020) -
Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
por: Joachim, Agricola, et al.
Publicado: (2020) -
The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers—A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania
por: Faini, Diana, et al.
Publicado: (2022)